GLP-1 medications delay gastric emptying, which theoretically may slow intestinal transit further and worsen constipation
The 4 mg dose in TRIUMPH-1 showed AE-driven discontinuation rates lower than placebo
Saltarella I, Morabito F, Giuliani N, Terragna C, Omed P, Palumbo A, et al
Abuarij, M., Alyahawi, A., & Alkaf, A
This body of research is part of why Tesamorelin is frequently used as a comparison anchor when researchers evaluate other peptides effects on fat metabolism
Current preoperative assessment for patients treated with GLP-1 RAs emphasizes individualized evaluation based on the route of administration, duration of therapy, and presence of gastrointestinal symptoms, suggesting that tailored management according to patient-specific risk is more appropriate than a uniform prolongation of fasting periods